Simplify Asset Management Inc. Buys 11,161 Shares of Johnson & Johnson $JNJ

Simplify Asset Management Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 50.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 33,121 shares of the company’s stock after acquiring an additional 11,161 shares during the quarter. Johnson & Johnson accounts for approximately 0.1% of Simplify Asset Management Inc.’s portfolio, making the stock its 24th largest holding. Simplify Asset Management Inc.’s holdings in Johnson & Johnson were worth $8,096,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Greenberg Financial Group purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $954,000. World Investment Advisors boosted its position in Johnson & Johnson by 19.6% in the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock worth $33,390,000 after purchasing an additional 26,450 shares during the last quarter. Coldstream Capital Management Inc. grew its stake in Johnson & Johnson by 9.8% in the 3rd quarter. Coldstream Capital Management Inc. now owns 95,662 shares of the company’s stock valued at $17,738,000 after purchasing an additional 8,533 shares during the period. Benchmark Financial LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $554,000. Finally, Sienna Gestion raised its stake in shares of Johnson & Johnson by 9.3% during the 3rd quarter. Sienna Gestion now owns 142,127 shares of the company’s stock worth $24,027,000 after purchasing an additional 12,073 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several research reports. Johnson Rice set a $270.00 price target on shares of Johnson & Johnson in a research report on Friday, June 26th. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 15th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $265.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 15th. Daiwa Securities Group raised their price target on shares of Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research note on Thursday, April 16th. Finally, TD Cowen started coverage on shares of Johnson & Johnson in a report on Wednesday, April 8th. They issued a “buy” rating and a $250.00 price target on the stock. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $257.13.

Johnson & Johnson Stock Performance

NYSE JNJ traded up $9.36 during trading on Tuesday, hitting $268.69. 1,799,409 shares of the company’s stock traded hands, compared to its average volume of 8,414,570. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The stock has a market capitalization of $646.80 billion, a price-to-earnings ratio of 31.02, a PEG ratio of 2.58 and a beta of 0.24. Johnson & Johnson has a 12-month low of $154.21 and a 12-month high of $268.88. The business has a 50 day moving average of $233.72 and a 200-day moving average of $231.37.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend was Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is presently 61.97%.

Insider Activity

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.